Human Life CORD Japan / ヒューマンライフコード株式会社

ENGLISH

Business
Description of Business

Mid- to long-term business vision of Human Life CORD
Through strategic business tie-ups that use an expansive network both inside and outside Japan, Human Life CORD preferentially introduces pipelines with higher development success rates or high independence.
We aim to secure profitability in the early stage in the medical device sector and accelerate the introduction of regenerative medicinal products to the market as soon as possible with the goal of achieving sustainable development.


Pipeline
Platform

●Personal history of President

Masamitsu Harata. Born August 29, 1972. In 1996, Masamitsu Harata studied the mechanism of human vascular endothelial cell proliferation at the Life Engineering Research Institute of the Agency of Industrial Science and Technology of the former Ministry of International Trade and Industry.
In 1998, he completed the master’s program in the Department of Bioresource Utilization Studies of the Graduate School of Agricultural Science at Gifu University.
In 2004, he completed development research on a new drug delivery system (DDS) for refractory hematologic cancer in the Division of Molecular Therapy Research at the University of Tokyo’s Institute of Medical Science.
From 1998, he worked in clinical development across several domains at Nippon Kayaku and Amgen, and obtained drug approval for hepatitis C. He joined Celgene in 2007 as a marketing manager and a senior manager in the Medical Affairs Department to build an internal sales system, as well as contribute to the success of launching a hematologic cancer drug on the market.
Subsequently, he was promoted and became the director of Clinical Development where he was involved in the management of several development programs.
In 2014, following his dream of becoming a corporate manager, he went to the United States to obtain an MBA in New York.
Upon returning home in 2015, he served as the chief business officer (CBO) and head of Sales and Marketing at SymBio Pharmaceuticals.
In 2017, he founded Human Life CORD, where he still works today. He is also a guest professor (part-time lecturer) at Nagoya University Graduate School of Medicine’s Department of Geriatrics and a member of the America-Japan society, Inc.
He was born in Nagoya, Aichi Prefecture and his hobbies are tennis, boxercise, reading, and watching movies.